Akeso Biopharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Akeso Biopharma, Inc. - overview
Established
2012
Location
Zhongshan, Guangdong, China
Primary Industry
Biotechnology
About
Established in 2012 and based in Zhongshan, China, Akeso Biopharma, Inc. operates as a biopharmaceutical company that provides biopharmaceutical R&D, production and commercialization. The company has many partners, such as Merck Sharp & Dohme, Summit Therapeutics and Dongrui Pharmaceuticals, etc. It has production base located in Guangzhou and Zhongshan and many offices located in Beijing, Shanghai and Nantong, etc.
In June 2018, it cooperated with GE to establish the first biologics production plant in South China using GE FlexFactory technology. In April 2020, the company was listed on the Hongkong stock exchange and its stock code is 9926. In August 2021, its product - Anicor® (PD-1 monoclonal antibody, pacamprinizumab injection) was approved for marketing. The company develops ACE platform and bispecific antibody development technology (Tetrabody.
Its product pipelines include AK129 (PD-1/LAG3), AK130 (TIGIT/TGFβ)、AK131 (PD-1/CD73), AK132 (Claudin18. 2/CD47) and AK117(CD47). Products include Ketanix® and Anicor®. It can apply in patients with oncology, autoimmune, inflammatory and metabolic diseases.
The company will plan to develop innovative drugs, promote clinical and establish production base.
Current Investors
CCB Principal Capital Management, Qianhai Xino, Phaeron Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.akesobio.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Akeso Biopharma, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|
| Revenue (USD) | 2,826,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (143,865,000) | - | - | - |
| Operating Income (USD) | (154,354,000) | - | - | - |
| Operating Margin | (5461.9%) | - | - | - |
| % EBITDA Margin | (5090.8%) | - | - | - |
| NET Income (USD) | (154,354,000) | - | - | - |
| % Net Margin | (5461.9%) | - | - | - |
Akeso Biopharma, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.